TABLE 1.
Patient demographics and baseline characteristics
| Cotadutide (n = 21) | Placebo (n = 20) | Total (N = 41) | |
|---|---|---|---|
| Age, years ± SD | 71.1 ± 7.4 | 70.9 ± 4.7 | 71.0 ± 6.1 |
| Sex, n (%) | |||
| Female | 9 (42.9) | 11 (55.0) | 20 (48.8) |
| Male | 12 (57.1) | 9 (45.0) | 21 (51.2) |
| Weight, kg; mean ± SD | 94.7 ± 17.6 | 91.6 ± 15.8 | 93.2 ± 16.6 |
| Height, cm; mean ± SD | 170.5 ± 9.8 | 167.0 ± 10.0 | 168.8 ± 10.0 |
| BMI, kg/m2; mean ± SD | 32.4 ± 4.1 | 32.9 ± 5.5 | 32.7 ± 4.8 |
| eGFR, ml/min/1.73 m2; mean ± SD | 44.7 ± 8.7 | 47.6 ± 8.8 | 46.1 ± 8.8 |
| HbA1c | |||
| %, mean ± SD | 7.85 ± 0.7 | 7.88 ± 1.3 | 7.87 ± 1.0 |
| mmol/mol, mean ± SD | 62 ± 7.7 | 63 ± 14.2 | 64 ± 10.9 |
| Fasting plasma glucose | |||
| mg/dl, mean ± SD | 166.6 ± 26.9 | 177.9 ± 50.7 | 172.1 ± 40.2 |
| mmol/L, mean ± SD | 9.3 ± 1.5 | 9.9 ± 2.8 | 9.6 ± 2.2 |
| Duration of type 2 diabetes, years; mean ± SD | 16.3 ± 8.5 | 15.9 ± 7.2 | 16.1 ± 7.8 |
| Insulin dose, n (%) | |||
| ≥20 units per day | 14 (66.7) | 14 (70.0) | 28 (68.3) |
| <20 units per day | 7 (33.3) | 6 (30.0) | 13 (31.7) |
| Other concomitant medications, n (%) | |||
| Metformin | 11 (52.4) | 9 (45.0) | 20 (48.8) |
| Sulphonylureas/glitinides | 6 (28.6) | 5 (25.0) | 11 (26.8) |
| SGLT2i | 4 (19.0) | 2 (10.0) | 6 (14.6) |
| DPP4i | 2 (9.5) | 3 (15.0) | 5 (12.2) |
| ACEi/A2RB | 16 (76.2) | 16 (80.0) | 32 (78.0) |
Abbreviations: A2RB, angiotensin II receptor blocker; ACEi, angiotensin‐converting enzyme inhibitor; BMI, body mass index; DPP4i, dipeptidyl‐peptidase 4 inhibitor; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; SD, standard deviation; SGLT2i, sodium‐glucose cotransporter 2 inhibitor.